Design and delivery of non-parenteral vaccines.

Non-parenteral delivery of vaccines is reviewed focusing on the delivery systems that have been used for various mucosal routes of administration. Systems considered include biodegradable micro- and nanoparticles, liposomes, live bacterial and viral vectors and mucosal adjuvants. New approaches to m...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 23; no. 4; pp. 257 - 286
Autores principales: Nugent J, Po AL, Scott EM
Formato: Journal Article
Publicado: Wiley-Blackwell Aug98
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105975004&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105975004
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Aug98
      vid: 23
      iid: 4
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        105975004
        2009782228
        NLM9867311
        105975004
      ppf: 257
      ppct: 29
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Design and delivery of non-parenteral vaccines.
      aug:
        au:
          Nugent J
          Po AL
          Scott EM
      sug:
        subj:
          Drug Delivery Systems
          Drug Design
          Vaccines Administration and Dosage
          Animals
          Antigens Metabolism
          Antigens Physiology
          Chemistry, Pharmaceutical
          Cytokines Physiology
          Immunity
          Immunoglobulins Physiology
          T Lymphocytes Physiology
      ab: Non-parenteral delivery of vaccines is reviewed focusing on the delivery systems that have been used for various mucosal routes of administration. Systems considered include biodegradable micro- and nanoparticles, liposomes, live bacterial and viral vectors and mucosal adjuvants. New approaches to mucosal vaccine formulation using: (i) gene fusion technology to create non-toxic derivatives of mucosal adjuvants, (ii) genetically inactivated antigens with a deletion in an essential gene, (iii) coexpression of an antigen and a specific cytokine that is important in the modulation and control of a mucosal immune response, and (iv) genetic material itself that would allow DNA or RNA uptake and its endogenous expression in the host cell are described.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N